Antifungal Resistance

Fungal pathogens are becoming increasingly difficult to treat as resistance to available therapies continues to rise across healthcare settings worldwide. Antifungal Resistance is now a growing concern, particularly among patients with weakened immune systems who rely heavily on effective antifungal treatments. The challenge is further intensified by the limited number of antifungal drug classes and the slow pace of new drug development. This session at the Infectious Diseases Conference focuses on understanding resistance patterns, identifying contributing factors, and exploring solutions to mitigate this emerging threat.

Resistance develops when fungal organisms adapt to survive exposure to antifungal agents, often through genetic mutations or biofilm formation. Overuse and misuse of antifungal medications in both clinical and agricultural settings accelerate this process. Invasive fungal infections caused by resistant strains are associated with higher morbidity, mortality, and healthcare costs. Additionally, delayed diagnosis and limited access to advanced diagnostics can further complicate treatment outcomes.

A closely related perspective, Fungal Drug Resistance, highlights the biological and clinical dimensions of this issue, emphasizing the need for targeted interventions. Strengthening antifungal stewardship programs, improving infection control practices, and enhancing surveillance systems are essential steps toward controlling resistance. Continued research into novel therapeutics and diagnostic tools is also critical to stay ahead of evolving pathogens. This session provides a comprehensive understanding of resistance mechanisms and equips participants with knowledge to improve clinical management and public health responses to antifungal resistance.